CDEX (Old)

[Viking65]

CDEX Announces "Implementation and Acceptance" of its ValiMed Patient Safety Solution

ROCKVILLE, MD and ANN ARBOR, MI – CDEX Inc. (OTCBB: CEXI) announces implementation and acceptance of its ValiMed Patient Safety Solution and Regulatory Compliance Solutions by the University of Michigan Health System following two months of testing. These ValiMed solutions are being utilized in the University’s C.S. Mott Children’s Hospital pharmacy to validate the compounding of high risk medications for pediatric patients’ individual doses as well as for batches of compounded injectable medications.

Issue: Medication Errors. According to the Institute of Medicine Report entitled To Err is Human: Building a Safer Health System, medication errors occur even though healthcare systems work diligently to eliminate them. Any process that utilizes humans is prone to errors. Ensuring that high risk medications are correctly compounded presents continual challenges to the pharmacy departments of busy institutions. Specific studies focused on sterile compounding have observed medication compounding errors in the dispensing process of pharmacies nationwide.

Solution: End Product Testing. The ValiMed solution offers pharmacies a quick, cost effective, simple tool to further ensure that the medication being dispensed is correctly compounded. ValiMed uses patent pending technology to validate compounded doses of high risk medications prior to dispensing them from the hospital pharmacy. The device performs tests in about 30 seconds and provides an added level of safety in the dispensing process when incorporated into a pharmacy's current system of checks for compounded medications.

“We are very pleased with our results and we feel that ValiMed can play a valuable role in improving the safety of the preparation of certain high risk products,” said Jim Stevenson, Director of Pharmacy at the University of Michigan. “The technology was easily integrated into our current dispensing process.”

“The partnership with Jim and his staff at the University of Michigan’s Pharmacy Department has been invaluable as we have continued to improve the capabilities of our proprietary technology,” said Malcolm Philips, CEO of CDEX. “The success at the University of Michigan shows the capability of our team to expand the use of the ValiMed device beyond our Impaired Clinician Solution and will be important as we continue to grow the capabilities of the healthcare product line in the future.”

C.S. Mott Children's Hospital, located in Ann Arbor, Michigan, is the children's hospital of the University of Michigan Health System. The 240-bed hospital provides care to more than 360,000 pediatric patients annually, and is ranked as one of the nation's top children's hospitals by Child magazine. For more information, visit www.med.umich.edu/mott and www.med.umich.edu/opm/newspage/2005/mottpharm.htm.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips or Jerry Blair at 301-881-0080 ([e-mail]).


Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.